In clinical neurology, smoking is recognised as one of the most significant modifiable risk factors affecting the course of Multiple Sclerosis (MS). Extensive research has demonstrated that tobacco use does not just increase the risk of developing the condition; it actively accelerates the progression of the disease and increases the severity of symptoms. For a person already diagnosed with MS, continuing to smoke is associated with a faster transition from relapsing remitting MS to secondary progressive MS.
The biological mechanisms behind this involve increased neuroinflammation and a more rapid loss of brain volume. Clinical guidelines strongly emphasise smoking cessation as a core component of MS management, alongside disease modifying therapies. This guide examines how smoking impacts the brain and spinal cord in MS and the tangible clinical benefits of quitting.
what we will discuss in this article
- The link between smoking and accelerated disability progression
- Impact on brain atrophy and lesion volume
- The increased risk of transitioning to secondary progressive MS (SPMS)
- How smoking reduces the effectiveness of certain MS medications
- The biological role of neuroinflammation and oxidative stress
- Clinical benefits of smoking cessation for long term outcomes
- emergency guidance for identifying signs of health deterioration
Acceleration of disability and disease progression
Smoking has a direct and measurable impact on the rate at which physical disability accumulates in individuals with MS.
Clinical studies consistently show that smokers with MS reach higher scores on the Expanded Disability Status Scale (EDSS) significantly faster than non smokers. This means that milestones such as requiring a walking aid or experiencing significant mobility impairment occur earlier. The toxins in cigarette smoke appear to exacerbate the underlying autoimmune attack on the myelin sheath, leading to more frequent relapses and incomplete recovery after an attack.
Impact on brain structure and neurodegeneration
Smoking is closely linked to more severe neurodegenerative changes in the central nervous system.
Patients who smoke tend to have a higher burden of T1 and T2 lesions on MRI scans compared to non smokers. More critically, smoking is associated with accelerated brain atrophy (shrinkage). This loss of brain volume, particularly in the grey matter, is a key predictor of cognitive decline and long term disability. The chemical components of tobacco smoke promote oxidative stress and activate microglia, the brain resident immune cells, which can lead to the destruction of healthy neurons alongside the damaged ones.
Transition to secondary progressive MS (SPMS)
One of the most concerning clinical findings is the role of smoking in the conversion of MS types.
Most people are initially diagnosed with relapsing remitting MS (RRMS). Over time, many transition to secondary progressive MS (SPMS), where disability accumulates steadily without clear relapses. Research indicates that smokers transition to this progressive phase several years earlier than those who have never smoked or who have quit. For every year a person continues to smoke after an MS diagnosis, the risk of transitioning to a progressive phenotype increases significantly.
Smoking and medication effectiveness
Smoking can interfere with the way the body responds to essential disease modifying therapies (DMTs).
In a clinical setting, we observe that smokers are more likely to develop neutralising antibodies against certain MS medications, such as interferons and natalizumab. These antibodies can make the treatment less effective or even completely inactive. Furthermore, the overall pro-inflammatory state created by smoking can counteract the anti-inflammatory goals of MS treatments, leading to a higher rate of breakthrough disease activity.
Comparison of outcomes: smokers vs non-smokers
| Clinical Metric | Smokers with MS | Non Smokers with MS |
| Disability Accumulation | Faster (higher EDSS scores) | Slower progression |
| Brain Atrophy Rate | Increased | Lower |
| Transition to SPMS | Occurs earlier | Occurs later |
| Lesion Volume on MRI | Generally higher | Generally lower |
| Response to Treatment | May be reduced by antibodies | Generally more predictable |
The benefits of smoking cessation
The good news is that the negative impact of smoking on MS is partially reversible or at least stoppable.
Clinical evidence suggests that as soon as a person quits smoking, the rate of disability progression begins to slow down, eventually matching the rate of someone who has never smoked. Quitting can lead to fewer relapses, a lower risk of transitioning to SPMS, and improved overall physical and cognitive health. In 2026, smoking cessation programs are often integrated directly into neurology clinics to provide patients with the support, nicotine replacement, or behavioural therapy needed to stop.
To summarise
Smoking significantly increases the severity of Multiple Sclerosis by accelerating physical disability, promoting brain atrophy, and hastening the transition to the progressive stages of the disease. It also compromises the effectiveness of vital medications. From a clinical perspective, quitting smoking is one of the most powerful actions a person with MS can take to protect their long term brain health and maintain their independence. While MS is a complex condition, eliminating this specific risk factor offers a clear path toward better outcomes and a slower disease course.
emergency guidance
While MS is a chronic condition, certain symptoms require immediate clinical evaluation to rule out other serious issues. Call 999 or seek urgent medical help if you experience a sudden onset of facial drooping, weakness on one side of the body, or slurred speech, as these can be signs of a stroke rather than an MS relapse. Additionally, any sudden and severe change in vision, such as a complete loss of sight in one eye, or a rapid onset of difficulty breathing or swallowing, constitutes a medical emergency. If you experience a sudden, intense fever alongside a dramatic worsening of your MS symptoms, you may have an underlying infection causing a pseudo-relapse, which needs prompt medical assessment.
Does vaping have the same effect on MS as smoking?
While vaping is generally considered less harmful than traditional cigarettes, nicotine itself is a vasoconstrictor that can affect blood flow to the brain. Research into vaping and MS is ongoing, but clinicians generally advise avoiding all nicotine products to minimise neuroinflammation.
How long after quitting does the risk decrease?
Some benefits, such as improved cardiovascular health, are immediate. Regarding MS progression, studies suggest that within a few years of quitting, the risk of transitioning to the progressive phase begins to align with that of non smokers.
I have smoked for years; is there any point in quitting now?
Yes. Stopping at any stage of the disease is beneficial. Quitting even after a transition to SPMS can help preserve remaining function and improve your overall quality of life and response to other treatments.
Why does smoking cause more lesions?
The toxins in smoke disrupt the blood brain barrier, making it easier for inflammatory immune cells to enter the central nervous system and attack the myelin sheath.
Can passive smoking affect my MS?
Yes. Exposure to second hand smoke has also been linked to an increased risk of developing MS and potentially a more severe disease course, as the pro inflammatory chemicals are still inhaled.
Does smoking affect MS related fatigue?
Yes. Smoking can worsen fatigue by affecting lung function and reducing the amount of oxygen reaching the brain and muscles, adding to the neurogenic fatigue already caused by MS.
Authority Snapshot
Dr. Stefan Petrov is a UK trained physician with an MBBS and postgraduate certifications including Basic Life Support BLS, Advanced Cardiac Life Support ACLS, and the UK Medical Licensing Assessment PLAB 1 and 2. He has hands on experience in general medicine, surgery, anaesthesia, ophthalmology, and emergency care. Dr. Petrov has worked in both hospital wards and intensive care units, performing diagnostic and therapeutic procedures, and has contributed to medical education by creating patient focused health content and teaching clinical skills to junior doctors in 2026.
